Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 15, 2008, Pages 2717-2726

  Carney, Darrell H ^a   Olszewska Pazdrak, Barbara ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Angiogenesis; Chronic wounds; Diabetic foot ulcers; Endothelial dysfunction; Fracture repair; Osteoporosis; Rusalatide acetate

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; ANGIOGENESIS MODULATOR; ANGIOTENSIN DERIVATIVE; ATORVASTATIN; BECAPLERMIN; CHRYSALIN; DSC 127; GAM 501; NITRIC OXIDE; PARATHYROID HORMONE[1-31][27 LEUCINE] AMIDE 22,26 AMIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT LACTOFERRIN; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; TELBERMIN; TP 508; UNCLASSIFIED DRUG;

ADULT STEM CELL; ARTICLE; CLINICAL TRIAL; DEBRIDEMENT; DIABETIC FOOT; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; FRAGILITY FRACTURE; GENE THERAPY; HUMAN; NONHUMAN; OPEN FRACTURE; OSTEOPENIA; PHARMACODYNAMICS; SINGLE DRUG DOSE; SKIN GRAFT; SPINE FUSION; TIBIA FRACTURE; TOXICITY TESTING; WOUND DRESSING; WOUND HEALING;

AMINO ACID SEQUENCE; CLINICAL TRIALS AS TOPIC; DIABETIC FOOT; FRACTURE HEALING; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; THROMBIN;

EID: 55249122720     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.15.2717     Document Type: Article

References (77)

1. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in wound healing. Am J Surg 1998;176:80S-82S
2. Nemeth GG, Bolander ME, Martin GR. Growth factors and their role in wound and fracture healing. Prog Clin Biol Res 1988;266:1-17
3. Fife C, Mader JT, Stone J, et al. Thrombin peptide Chrysalinö stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Wound Repair Regen 2007;15:23-34
4. Ryaby JT, Sheller MR, Levine BP, et al. Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. J Bone Joint Surg Am 2006;88(Suppl 3):132-9
5. Ladd AL, Shin AYS, Bramler DG, et al. Phase 3 acceleration of distal radius fracture healing with a thrombin receptor binding peptide. OrthoLogic Web Site 2007. Available from: http://www.orthologic.com/ research-development/chrysalinTP508.php [Accessed 14 May 2008]
6. Olszewska-Pazdrak B, Bergmann JS, Fuller GM, et al. Thrombin and thrombin peptides in wound healing and tissue repair. In: Tsopanoglou N, Maragoudakis M, editors, Thrombin: health and diseases. Springer, New York; 2008
7. Greenhalgh DG. Wound healing and diabetes mellitus. Clin Plast Surg 2003;30:37-45
8. Millington JT, Ellenzweig J. The comprehensive therapy of diabetic foot ulcers. Compr Ther 2005;31:50-8
9. Cavanagh PR, Lipsky BA, Bradbury AW, et al. Treatment for diabetic foot ulcers. Lancet 2005;366:1725-35
10. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366:1736-43
11. Mansbridge J. Skin substitutes to enhance wound healing. Expert Opin Investig Drugs 1998;7:803-9
12. Saldalamacchia G, Lapice E, Cuomo V, et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutr Metab Cardiovasc Dis 2004;14:395-6
13. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006;117:l43S-149S; discussion 150S-151S
14. Nagai MK, Embil JM. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2002;2:211-8
15. Tzioupis C, Giannoudis PV. Prevalence of long-bone non-unions. Injury 2007;38(Suppl 2):S3-9
16. King AR, Moran SL, Steinmann SP. Humeral nonunion. Hand Clin 2007;23:449-56
17. Giannoudis PV, Tzioupis C. Clinical applications of BMP-7: the UK perspective. Injury 2005;36(Suppl 3):S47-50
18. Vaibhav B, Nilesh P, Vikram S, et al. Bone morphogenic protein and its application in trauma cases: a current concept update. Injury 2007;38:1227-35
19. Hollister C, Li VW. Using angiogenesis in chronic wound care with becaplermin and oxidized regenerated cellulose/collagen. Nurs Clin North Am 2007;42:457-65
20. Margolis DJ, Kantor J, Santanna J, et al. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001;24:483-8
21. Cha J, Falanga V. Stem cells in cutaneous wound healing. Clin Dermatol 2007;25:73-8
22. World Health Organization. 2008. Available from: http://www.who.int/ diabetes/facts/world_figures/en/ [Accessed 24 August 2008]
23. Fard AS, Esmaelzadeh M, Larijani B. Assessment and treatment of diabetic foot ulcer. Int J Clin Pract 2007;61:1931-8
24. Consensus Development Conference on Diabetic Foot Wound Care. Adv Wound Care 1999;12:353-61
25. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, et al. The global burden of diabetic foot disease. Lancet 2005;366:1719-24
26. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003;26:491-4
27. Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002;19:483-91
28. Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996;183:61-4
29. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:822-7
30. Smiell JM, Wieman TJ, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999;7:335-46
31. Ark J, Jupiter JB. The rationale for precise management of distal radius fractures. Orthop Clin North Am 1993;24:205-10
32. Delmas PD, Fraser M. Strong bones in later life: luxury or necessity? Bull World Health Organ 1999;77:416-22
33. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
34. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997;103:20S-25S; discussion 25S-26S
35. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
36. Garrison KR, Donell S, Ryder J, et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review: Health Technol Assess 2007;11:1-150
37. Dahabreh Z, Dimitriou R, Giannoudis PV. Health economics: a cost analysis of treatment of persistent fracture non-unions using bone morphogenetic protein-7. Injury 2007;38:371-7
38. Giannoudis P, Psarakis S, Kontakis G. Can we accelerate fracture healing? A critical analysis of the literature. Injury 2007;38(Suppl 1):S81-9
39. Robinson Y, Heyde CE, Tschoke SK, et al. Evidence supporting the use of bone morphogenetic proteins for spinal fusion surgery. Expert Rev Med Devices 2008;5:75-84
40. Glenn KC, Frost GH, Bergmann JS, et al. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Peptide Res 1988;1:65-73
41. Stiernberg J, Redin WR, Warner WS, et al. The role of thrombin and thrombin receptor activating peptide (TRAP-508) in initiation of tissue repair. Thromb Haemostasis 1993;70:158-62
42. Wang H, Li X, Tomin E, et al. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res 2005;23:671-9
43. Li X, Wang H, Touma E, et al. TP508 accelerates fracture repair by promoting cell growth over cell death. Biochem Biophys Res Commun 2007;364:187-93
44. Olszewska-Pazdrak B, Hart Van-Tassel A, Carney DH. Thrombin peptide TP508 upregulates expression and activation of eNOS and prevent hypoxia-induced eNOS downregulation in human endothelia] cells. Mol Biol Cell 2006;17(Suppl):A2654
45. Olszewska-Pazdrak B, Hein T, Carney DH. Effects of thrombin peptide TP508 on cultured endothelial cells suggest a wound healing mode of action that involves reversal of endothelial dysfunction. Wound Repair Regen 2007;15:A32
46. Fossum TW, Olszewska-Pazdrak B, Mertens MM, et al. Thrombin peptide TP508 prevents endothelial dysfunction and restores myocardial function in hearts with chronic ischemia. J Cardiovasc Pharmacol Ther 2008;13:214-25
47. Voisine P, Li J, Bianchi C, et al. Effects of L-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction. Circulation 2005;112:1202-7
48. Parenti A, Morbidelli L, Cui XL, et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998;273:4220-6
49. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000;477:258-62
50. Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007;117:1249-59
51. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007;117:1219-22
52. Burrow JW, Koch JA, Chuang HH, et al. Nitric oxide donors selectively reduce the expression of matrix metalloproteinases-8 and -9 by human diabetic skin fibroblasts. J Surg Res 2007;140:90-8
53. Carney DH, Mann R, Redin WR, et al. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 1992;89:1469-77
54. Stiernberg J, Norfleet AM, Redin WR, et al. Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508. Wound Repair Regen 2000;8:204-15
55. Norfleet AM, Bergmann JS, Carney DH. Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells. Gen Pharmacol 2000;35:249-54
56. Cevera JJ, Bolton LL, Kerstein MD. Options for diabetic patients with chronic heel ulcers. J Diabetes Complications 1997;11:358-66
57. Hampton S. The complexities of heel ulcers. Nurs Stand 2003;17:68-70, 72, 74
58. Younes NA, Albsoul AM, Awad H. Diabetic heel ulcers: a major risk factor for lower extremity amputation. Ostomy Wound Manage 2004;50:50-60
59. Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998;47:457-63
60. Boykin JV Jr. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management. Adv Skin Wound Care 2000;13:169-74
61. Lobmann R, Ambrosch A, Schultz G, et al. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002;45:1011-6
62. Masters KS, Leibovich SJ, Belem P, et al. Effects of nitric oxide releasing poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice. Wound Repair Regen 2002;10:286-94
63. Van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology 2001;103:255-61
64. Diwan AD, Wang MX, Jang D, et al. Nitric oxide modulates fracture healing. J Bone Miner Res 2000;15:342-51
65. Namkung-Matthai H, Diwan A, Mason RS, et al. Nitric oxide regulates alkaline phosphatase activity in rat fracture callus explant cultures. Redox Rep 2000;5:126-7
66. Evans CH, Stefanovic-Racic M, Lancaster J. Nitric oxide and its role in orthopaedic disease. Clin Orthop Relat Res 1995;312:275-94
67. Sanada M, Taguchi A, Higashi Y, et al. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis 2004;176:387-92
68. Genentech. Genentech Announces full year and fourth quarter 2007 results 14 Jan 2008 (See Clinical Developments): Financial Press Releases 2008. Available from: http://www.gene.com/gene/news/press-releases/ [Accessed 24 August 2008]
69. Trials.gov, C. Safety and efficacy study of MRE0094 to treat large, single or multiple, chronic neuropathic diabetic foot ulcers. 9 June 2008. Available from: http://clinicaltrials.gov/ct2/show/ ?term=MRE0094&rank=1 [Accessed 24 August 2008]
70. Gulcan E, Gulcan A, Erbilen E, et al. Statins may be useful in diabetic foot ulceration treatment and prevention. Med Hypotheses 2007;69:1313-5
71. Whitney C, Warburton DE, Frohlich J, et al. Are cardiovascular disease and osteoporosis directly linked? Sports Med 2004;34:779-807
72. Arana V, Paz Y, Gonzalez A, et al. Healing of diabetic foot ulcers in L-arginine-treated patients. Biomed Pharmacother 2004;58:588-97
73. FDA Announces new labeling changes for regranex. FDA News 2008. Available from: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01845.html [Accessed 13 June 2008]
74. Shami PJ, Saavedra JE, Bonifant CL, et al. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem 2006;49:4356-66
75. Morganti M, Carpi A, Nicolini A, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother 2002;56:317-24
76. Sheller MR, Crowther RS, Kinney JH, et al. Repair of rabbit segmental defects with the thrombin peptide, TP508. J Orthop Res 2004;22:1094-9
77. Hedberg EL, Kroese-Deutman HC, Shih CK, et al. Effect of varied release kinetics of the osteogenic thrombin pepride TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J Biomed Mater Res A 2005;72:343-53